Mark Osier is a preclinical research scientist with broad experience in toxicology covering more than 25 years. He obtained his PhD in Pharmacology and Toxicology from the University of Rochester with a focus in inhaled particles and is board-certified in toxicology. Mark has contributed to drug development programs in the inflammation, oncology, cardiovascular, antiviral, and fibrosis therapeutic areas on projects involving small molecules, therapeutic proteins, and oligonucleotides.  He is currently President of Willow Toxicology Consulting and previously was Director of Toxicology at Neurocrine Biosciences, Director and Head of Toxicology at Pliant Therapeutics, Director of Toxicology at Gilead Sciences, Senior Scientist/Study Director at SNBL USA, and Scientist at Syracuse Research Corporation.